A compelling opportunity to unlock growth, profitability & returns
A compelling opportunity to unlock growth, profitability & returns
BI-Oxy GmbH., previously OxMed Inc, is a Germany-based corporation registered in Dusseldorf, with a base in Freiburg. “The Company” is currently in the process of developing a breakthrough medical in the extracorporeal membrane oxygenation (ECMO) and oxygen therapy field that has the potential to completely reshape the market.
Original ECMO devices were intended for severely compromised respiratory and cardiac patients, such as patients undergo complications in open chest surgery. Since there are no alternative devices for moderately compromised respiratory and cardiac patients, such as COVID-19 and emphysema patients, the same ECMO devices were used. Some improvements were introduced to the original ECMO device by miniaturizing the system and making it transportable. Present ECMO devices depend on hospital oxygen supply or to carry a limited amount of oxygen in an oxygen tank that last for an hour or so. These facts limit the expansion of such markets.
Bi-Oxy technology could potentially increase hospital capacity by several folds by mobilizing moderately affected patients, such as COVID-19 patients, and freeing hospital beds. With the Bi-Oxy system moderately ill patients or severely affected patients that improved while in the hospital, could be mobilized to a low care center and therefore freeing a hospital bed.
It is anticipated with a breakthrough technology, like Bi-Oxy technology, the market could be increased from half a million yearly case to several million cases per year. Bi-Oxy offers a pulmonary and/or heart assist that will allows patient’s mobility for hours independent of hospital oxygen supply and without the burden of carrying an oxygen tank or any extra weight. Bi-Oxy technology could potentially increase hospital capacity by several folds by mobilizing moderately affected patients, such as COVID-19 patients.
BI-Oxy offers significant improvement over current market players both from a functional and operational standpoint (mobility, size, efficiency, lower cost of medical treatment etc.). As such, once we establish proof of concept, the device has the potential to reshape the market and capture significant market share from competitors.
ECMO is a way to provide oxygen to the blood supply.
ECMO devices act as an artificial lung called a membrane oxygenator to enrich the blood with oxygen.
ECMO is an institutional form of life support that can save people suffering from a severe respiratory condition.